We scan new podcasts and send you the top 5 insights daily.
Greg Crescenzi says Addgene has received over 15,000 CRISPR plasmid deposits, including foundational materials, and those have generated 300,000 shipments to 5,000 organizations. That shipment volume shows how a central repository prevents many labs from separately rebuilding the same validated tools and wasting time and money.
Malina Fan spent months trying to get plasmids, then realized depositing scientists wanted to share but lacked time and infrastructure. Greg Crescenzi says Addgene took over storage, logistics, legal agreements, QC, and curation, removing the burden from both requesters and institutions shipping materials so sharing could scale.
Greg Crescenzi says 90% of Addgene's COVID deposits and resources were made available to industry during the pandemic, enabling a faster collective response. Addgene now wants to extend that same industry access to much of its other translational material, not just crisis-specific reagents, according to him.
The challenge with pooled screening is isolating the single best clone. A novel approach uses a CRISPR activation system that specifically targets the winning clone's unique DNA barcode. This activates a selectable marker, enabling the high-precision extraction of the desired cell line for monoclonal expansion.
Greg Crescenzi defines success as materials, methods, and even results flowing freely by default between academia and industry. Restricting access should be a conscious exception, he says. He also wants industry to share unpublished experiment information, including failures, because that knowledge is valuable to others.
Traditionally, vector design and cell line development are sequential steps requiring intermediate tests. By screening a mixed pool of candidates with DNA barcodes directly in a bioreactor, these stages can be overlapped, accelerating the timeline from initial design to identifying a high-performing manufacturing clone.
Greg Crescenzi says Addgene's Solid Bio deal brings a therapeutic company's technology to academic and industry labs. Addgene already sells NEB and Promega products and wants more such partnerships, making reagent sharing flow from industry to academia as well as the reverse, according to him.
The Innovative Genomics Institute is tackling rare diseases by creating a standardized platform. By keeping elements like the delivery vehicle and enzyme constant and only changing the guide RNA, they aim to create a repeatable 'bucket trial' process for developing hundreds of cures, not just one-offs.
Greg Crescenzi says Addgene holds historical, curated information that no one else has and is talking with software and AI companies about partnerships. He sees AI today as rapidly changing the space and wants Addgene's archive to support new data and information products, he says.
The innovation pipeline in biotech often starts in academia with fundamental breakthroughs like CRISPR or single-cell sequencing. Industry then provides the resources and engineering mindset to scale these technologies, robustify them, and generate the massive, high-quality datasets required to power AI-driven discovery.
Cell by Gene began as a tool to solve an internal data annotation bottleneck. By open-sourcing it, CZI unintentionally created a standard data format. The broader scientific community adopted the tool for its utility, organically creating a massive, shared cell atlas built by many contributors, not just CZI.